Citations

Clear

124 citation(s) found for "Kramer, Joel".

Smartphone Passive Digital Phenotyping in Frontotemporal Lobar Degeneration
Paolillo, Emily W. , Dhanam, Sreya , Taylor, Jack C. , Sanderson-Cimino, Mark, Fregly, Ray, Saloner, Rowan, Casaletto, Kaitlin B, Kramer, Joel H, Miller, Bruce L, Seeley, William W, Gorno-Tempini, Maria Luisa, Ljubenkov, Peter A. , Rojas, Julio C, Lee, Suzee, Sturm, Virginia, Appleby, Brian, Bayram, Ece, Clark, David, Considine, Ciaran , Darby, R. Ryan , Day, Gregory S, Vito, Alyssa , Eldaief, Mark, Fields, Julie A. , Ghoshal, Nupur , Huey, Edward D, Irwin, David J, Kantarci, Kejal, Kwan, Justin , Mackenzie, Ian R. , Masdeu, Joseph C, Onyike, Chiadi U, Pantelyat, Alexander, Pascual, Belén , Popli, Tanav, Rascovsky, Katya, Rezaii, Neguine , Scholz, Sonja W. , Snyder, Allison , Tartaglia, Maria Carmela , Traynor, Bryan J, Wong, Bonnie, Kornak, John , Kremers, Walter K. , Forsberg, Leah K. , Heuer, Hilary W. , Boeve, Bradley F. , Rosen, Howard J, Boxer, Adam L, Staffaroni, Adam M. , Sanderson‐Cimino, Mark , Saloner, Rowan , Casaletto, Kaitlin B. , Kramer, Joel H. , Miller, Bruce L. , Seeley, William W. , Gorno‐Tempini, Maria Luisa , Rojas, Julio C. , Sturm, Virginia E. , Appleby, Brian S. , Day, Gregory S, Vito, Alyssa De, Eldaief, Mark C. , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Masdeu, Joseph, Onyike, Chiadi U. , Popli, Tanav A. , Tartaglia, Maria Carmela , Traynor, Bryan J. , Rosen, Howard J. , Boxer, Adam L.

Mayo Clinic

No container title available | September 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.18.26363439 | PMID 42818136 Get It

Introduction: Frontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials. Remote monitoring via low-burden digital health tools may overcome these barriers. We evaluated clinical utility of passive smartphone monitoring in FTLD using a multi-domain mobile assessment platform. Methods: Participants were 567 adults (53% clinically normal, 21% prodromal FTLD, 26% symptomatic FTLD) who completed an in-person study visit and downloaded the ALLFTD Mobile App on their personal smartphones. The app delivered unsupervised cognitive tests and passively collected continuous data on battery percentage (proxy for smartphone use) and step count. Longitudinal follow-up included smartphone monitoring and annual in-person study visits. Primary analyses examined associations between passive smartphone features and markers of disease severity at baseline and longitudinally, and tested whether passive features added incremental value beyond app-based cognitive testing. Results: Passive smartphone features were feasible to collect and showed excellent reliability with <2 weeks of monitoring (ICCs>0.9). Features capturing smartphone use and movement demonstrated sensitivity to gold-standard clinical measures of disease severity both at baseline and longitudinally. A classification model combining passive features, the app-based cognitive composite score, and demographics detected longitudinal functional decline (AUC=0.89); passive features alone (AUC=0.84) performed comparably to a cognitive screener (AUC=0.85). Discussion: Passive smartphone monitoring is a valid, zero-burden measure of disease severity and progression in FTLD that adds modest incremental value beyond app-based cognitive testing. Findings support its use as a scalable digital endpoint in longitudinal FTLD research.
Plasma proteomics reveals molecular overlap between physical activity and dementia risk
Saloner, Rowan , Cadwallader, Claire J. , Chen, Coty , Boeve, Bradley F. , Rosen, Howard J. , Boxer, Adam L, Kramer, Joel H, Casaletto, Kaitlin B. , Bennett, David A. , Boeve, Brad , Casaletto, Kaitlin B , Paolillo, Emily W. , VandeBunte, Anna M. , Steffen, Brian T. , Bennett, David A. , Boxer, Adam L. , Kramer, Joel H.

Mayo Clinic

Brain Communications | July 20, 2026 | Volume: 8 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcag287 | PMID 42540732 Get It

Abstract Physical activity (PA) is a modifiable lifestyle behaviour associated with lower dementia risk; however, molecular pathways bridging PA-related dementia prevention are poorly understood. We leveraged large-scale plasma proteomics to identify biological signatures of objectively monitored PA and cognitive ageing in functionally intact older adults, cross-validated these signatures in independent exercise cohorts and tested associations with both symptomatic and presymptomatic stages of neurodegeneration across multiple Alzheimer’s disease and related dementias (ADRD) cohorts. We analysed large-scale plasma proteomics data (SomaScan 7k) across three cohorts including naturalistic, objective PA monitoring (University of California, San Francisco Brain Aging Network for Cognitive Health cohort, n = 65), self-reported PA (Atherosclerosis Risk In Communities study, n = 10 644) and PA intervention (Health Risk Factors, Exercise Training and Genetics study, n = 654). Differential regression models examined individual protein correlates of PA, adjusting for age and sex. Weighted gene co-expression network analysis assembled proteins into unbiased modules of protein co-expression, which were annotated for gene ontology and cell-type enrichment. To test clinical relevance to ADRD, we examined PA-related protein levels across-cohorts of symptomatic Alzheimer’s disease and Parkinson’s disease (Stanford Alzheimer’s Disease Research Center), as well as frontotemporal dementia-spectrum disorders (ARTFL/LEFFTDS Longitudinal Frontotemporal Lobar Degeneration consortium). PA-related plasma proteins were also tested as predictors of antemortem cognitive change and post-mortem brain tissue mass spectrometry proteomic signatures in brain donors from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP) cohort. Differential regression and network analyses identified PA plasma proteomic signatures linked to cell adhesion/extracellular matrix (ECM), immune response and lipid metabolism. Protein co-expression module M12 ECM/neurodevelopment harboured growth factor, cell adhesion and vascular remodelling proteins that (i) were positively associated with PA across exercise cohorts, (ii) positively associated with cognitive function and (iii) negatively associated with Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia. Furthermore, M12 was enriched for proteins from Alzheimer’s disease risk genes and antemortem plasma abundance of anthrax toxin receptor cell adhesion molecule 2 (ANTXR2), an M12 ‘hub’ protein and top PA hit across-cohorts, forecasted longitudinal global cognitive decline and post-mortem brain tissue signatures of synaptic function and proteolysis in ROSMAP. Collectively, our integrated systems biology analysis of six independent plasma proteomic datasets facilitated discovery and validation of blood-detectable molecular signatures of PA and neurodegenerative disease, including PA-related proteins with clinical and biological relevance to early stages of disease. Circulating levels of PA-related proteins reflecting ECM biology (e.g. ANTXR2) may represent key molecular targets for dementia prevention.
Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease
Soleimani‐Meigooni, David N. , Chiotis, Konstantinos, Allen, Isabel E., Rabinovici, Gil D., Joie, Renaud La , Group, Meta-Centiloid Study, Apostolova, Liana G. , Asken, Breton M., Benzinger, Th., Betthauser, Tobey J., Bluma, Marina, Bombois, Stephanie, Bourgeat, Pierrick, Bouteloup, Vincent , Braskie, Meredith N., Brendel, Matthias, Brickman, Adam M., Bryant, Natalie, Bullich, Santiago , Carrillo, Maria C., Casaletto, Kaitlin, Cash, David M., Chang, Chiung-Chih, CHANG, H L, Chao, Yishu , Collij, Lyduine E., Corrada, Maria M., Craft, Suzanne , Dickerson, Bradford C., Dubois, Bruno, Dufouil, Carole, Fajardo, Alfonso, Farrar, Gill , Fortea, Juan, Frings, Lars , Frisoni, Giovanni B., Gardner, Raquel C., Gnörich, Johannes , Gordon, Brian A., Gu, Yuna , Guan, Yihui, Guo, Tengfei, Hanseeuw, Bernard J., Hansson, Oskar, Harrison, Theresa M., Huang, Qi, Huang, ST , Iaccarino, Leonardo, Ishii, Kazunari, Ishi, Kenji, Jagust, William J., Johnson, Sterling C., Kato, Takashi, Katsumi, Yuta, Kaye, Jeffrey, Kolinger, Guilherme D., Kramer, Joel H. , Landau, Susan M., Landeau, Brigitte, Lao, Patrick J., Lee, Sangwon, Lopresti, Brian J., Lowe, Val J. , Luchsinger, José A., Mao, Xiaoxie, March, Andrew, Masters, Colin L., Meyer, Philipp T., Mezenge, Florence, Mormino, Elizabeth C., Franquesa‐Mullerat, María , Nakamura, Akinori, Nordberg, Agneta, O’Brien, John T., O’Bryant, Sid E., Pappas, Ioannis, Peretti, Debora E., Rowe, Christopher C., Rowe, James B., Schwartz, Daniel L., Seo, Sang Won , Shekari, Mahnaz, Smith, Ruben, Snyder, Heather M. , Sokolowski, Andrzej, Sperling, Reisa A., Sun, Pan, Taggett, Jacinda Z., Touroutoglou, Alexandra , Vaillancourt, David E., Giessen, Elsmarieke van de, Vijverberg, Jort, Villemagne, Victor L. , Villeneuve, Sylvia , Wang, Wei-en, Weiner, Michael, Woodworth, Davis, Xiao, Cally , Xie, F, Yoon, Yeojun, Yun, Mijin, Severanc, A4, ABIDE, ADNI*, ADNI-DoD, AgeWell, AIBL, AMYPAD, BACS, BATON, BIOCARD, BLSA, BioFINDER-2, BrANCH, CPAS, DETECT-AD, GEMS, GHABS, HABS, HABS-HD, IDEAS, IMAP, INSIGHT-preAD, Insight46, K-ROAD, LEADS, MCSA, MULNIAD, MEMENTO, SCAN, PREVENT-AD, SPIN,, Corrada, María M. , La Joie, Renaud , Blazhenets, Ganna , Chiotis, Konstantinos , Allen, Isabel Elaine , Rabinovici, Gil D. , Asken, Breton M. , Bejanin, Alexandre , Benzinger, Tammie L.S. , Betthauser, Tobey J. , Blūma, Marina , Bombois, Stéphanie , Bourgeat, Pierrick , Braskie, Meredith N. , Brendel, Matthias , Brickman, Adam M. , Carrillo, María C. , Casaletto, Kaitlin B. , Cash, David M. , Chang, Chiung‐Chih , Chang, Hsin‐I , Chêne, Geneviève , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Bradford Clark , Dubois, Bruno , Dufouil, Carole , Fortea, Juan , Garibotto, Valentina , Gordon, Brian A. , Guan, Yihui , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Iaccarino, Leonardo , Ishii, Kazunari , Ishii, Kenji, Jagust, William J. , Johnson, Sterling C. , Katsumi, Yuta , Kaye, Jeffrey , Koeppe, Robert A. , Kolinger, Guilherme Domingues , Landau, Susan , Landeau, Brigitte , Lao, Patrick , Lee, Sangwon, Lleó, Alberto , Lopresti, Brian J. , Malpetti, Maura , March, Andrew, Masters, Colin L. , Mézenge, Florence, Mormino, Elizabeth C. , Nakamura, Akinori , Nordberg, Agneta , O'Brien, John Tiernan , O’Bryant, Sid E. , Pappas, Ioannis , Quenon, Lisa , Rowe, Christopher Cleon , Rowe, James B. , Rudolph, Marc D. , Salvadó, Gemma , Schott, Jonathan M. , Schwarz, Christopher G. , Shekari, Mahnaz , Silbert, Lisa C. , Smith, Ruben, Sokolowski, Andrzej, Sperling, Reisa Anne , Sun, Pan , Taggett, Jacinda , Toga, Arthur W. , Vaillancourt, David E. , Giessen, Elsmarieke van de , Vemuri, Prashanthi , Villain, Nicolas , Wang, Wei‐en , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Yun, M R

Mayo Clinic

JAMA | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.13116 | PMID 42441390 Get It

Importance Amyloid positron emission tomography (PET) is increasingly used in research and clinical settings to determine the etiology of cognitive decline and eligibility for amyloid-targeting therapies. To assist with amyloid PET evaluation and to guide clinical decision-making, images can be quantified in a standardized unit called Centiloid, the interpretation of which can vary according to the method and threshold used. Objective To collect Centiloid values from available studies and determine robust positivity cutoffs using data-driven methods and correspondence with visual reads. Data Sources PubMed search (October 2024) identified studies with Centiloid values. Corresponding authors were invited to share individual participant data. Additional data were obtained through access-controlled repositories and conference outreach (July 2024-July 2025). Study Selection Studies were included if they provided Centiloids, radiotracer, age, and sex. Data Extraction and Synthesis Each study was analyzed using a unified statistical pipeline; study estimates were pooled using random-effects meta-analysis. Main Outcomes and Measures Gaussian mixture models (GMMs) were fitted to Centiloid values for each study. In studies with a bimodal distribution (per integrated completed likelihood), single cutoffs for positivity were set as mean plus 2 SDs of the lower gaussian component. Using GMMs, a double-cutoff approach defined a lower certainty range using a 90% posterior probability cutoff for assignment to the low (amyloid-negative) vs high (amyloid-positive) component. An alternative Centiloid cutoff was derived from maximizing the correspondence (Cohen κ) with the binary visual reads when available. Results This meta-analysis included cross-sectional amyloid PET scans acquired with 5 radiotracers from 49 227 participants across 53 studies from 15 countries (mean age, 71 years; 54% female, 62% cognitively impaired). The data-driven GMM approach identified a bimodal distribution in 51 studies (n = 48 786), resulting in a single cutoff for positivity of 18 Centiloids (95% CI,16-19; I 2 = 97%). The double-cutoff approach revealed high confidence for interpreting scans as negative when Centiloid values were lower than 11 (95% CI, 9-13; I 2 = 95%) and interpreting scans as positive if Centiloid values were higher than 26 (95% CI, 24-28; I 2 = 95%). In analyses of correspondence with binary (positive or negative) visual reads of amyloid PET scans (n = 35 045; 36 studies), Centiloids were highly predictive of visual positivity (Cohen κ, 0.86; 95% CI, 0.83-0.89; I 2 = 96%) with a cutoff of 27 Centiloids (95% CI, 24-30; I 2 = 80%). Conclusions and Relevance In this individual participant data meta-analysis, positivity cutoffs converged around 18 Centiloids (data-driven) and 27 Centiloids (visual reads). Findings from a double-cutoff analysis suggest that scans in the 11 to 26 Centiloid range should be interpreted with caution depending on the context of use.
In-clinic validation of a smartphone-based finger tapping test for use in neurodegenerative and neurological populations
O'Connor, Morgan, Sanderson‐Cimino, Mark , Li, Zi , Dhanam, Sreya , Sadarangani, Anjali, Downer, Joshua, Fregly, Ray, Taylor, J M, Wise, Amy B. , Casaletto, Kaitlin B., Forsberg, Leah K. , Gorno-Tempini, Maria Luisa, Heuer, Hilary W. , Kramer, Joel H., Kornak, John , Miller, Bruce L, Bove, Riley , Rabinovici, Gil, Seeley, William W., Boeve, Brad F, Rosen, Howie, Boxer, Adam L., Staffaroni, Adam M. , Sanderson-Cimino, Mark E , Paolillo, Emily W , Bove, Riley , Staffaroni, Adam M , O'Connor, Morgan, Casaletto, Kaitlin B. , Gorno‐Tempini, Maria Luisa , Kramer, Joel H., Paolillo, Emily W. , Rabinovici, Gil D. , Seeley, William W. , Boxer, Adam L.

Mayo Clinic

No container title available | July 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.25.26356467 | PMID 42465936 Get It

Background Motor disturbances are common in neurologic and neurodegenerative syndromes. A standard motor speed and dexterity measure is the finger tapping test (FTT). The FTT has traditionally been administered in clinic using a mechanical FTT, limiting accessibility and early motor change quantification. This study assessed the validity of a smartphone app-based FTT, which may expand access and enable more frequent testing. Methods The cohort was diagnostically diverse, including participants with frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), corticobasal syndrome, primary progressive aphasia, multiple sclerosis, and clinically unimpaired controls. Participants completed a 20-second ALLFTD Mobile App (mApp)-FTT with each hand. Tapping speed metrics were extracted. Participants completed the gold-standard mechanical FTT, a neurologist-administered finger tapping exam, the PSP Rating Scale (PSPRS) and the Unified Parkinson’s Disease Rating Scale (UPDRS). Correlations assessed mApp-FTT and mechanical FTT relationships; regressions evaluated associations with neurologist-rated finger tapping impairment, PSPRS and UPDRS, adjusting for age and sex. Results The mApp-FTT showed moderate-to-strong correlations with the mechanical FTT (dominant: r=0.63, p<0.001; non-dominant: r=0.55, p<0.001). Taps per second were associated with PSPRS motor severity (dominant hand: std. β=-0.59, 95% CI [-0.91, -0.27], p<0.001) and the UPDRS (dominant hand: std. β=-0.41, 95% CI [-0.82, 0.00], p=0.049). Flight time was modestly associated with neurologist-rated finger tapping impairment (dominant hand: std. β=0.15, 95% CI [0.00, 0.29], p=0.044). Conclusion These findings support mApp-FTT validity as a measure of motor function across neurodegenerative conditions. Validation in longitudinal and unsupervised remote settings is warranted to understand scalability and evaluate change over time.
Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia
Olzinski, Molly, Downer, Joshua, Rajbanshi, Binita, Li, Jingyao, Loureiro, Joseph, Heuer, Hilary, Ljubenkov, Peter, Vandevrede, Lawren, Staffaroni, Adam, Lario‐Lago, Argentina, Leichter, Dana, Wolf, Amy, Wise, Amy, Sanderson-Cimino, Mark, Barragan, Eden, Spina, S, Grinberg, Lea T., Seeley, William W., Casaletto, Kaitlin B., Kramer, Joel, Ramos, Eilana, Geschwind, Daniel, Cook, Casey, Petrucelli, L, Forsberg, Leah K., Gendron, Tania, Boeve, Bradley F., Rademakers, Rosa, Rosen, Howard J., Saloner, Rowan, Boxer, Adam L., Rojas, Julio C., Abdullah, M. Samy, Apostolova, Liana, Appleby, Brian, Bayram, Ece, Hp, Botha, Bozoki, Andrea, Brushaber, Danielle, Clark, David, Considine, Ciaran M., Darby, R. Ryan, Day, Gregory S., Dickerson, Bradford C., Dickson, Dennis, Domoto-Reilly, Kimiko, Dwosh, Emily, Faber, Kelley M., Fields, Julie A. , Fong, Jamie C., Foroud, Tatiana, Galasko, Douglas R., Gavrilova, Ralitza, Ghoshal, Nupur , Goldman, Jill, Graff-Radford, Jonathan, Graff-Radford, Neill, Grant, Ian M., Cn, Hales, Honig, Lawrence S., Gd, Hsiung, Huey, Edward D, Irwin, David, Jones, David T., Kantarci, Kejal, Knopman, David, Kolander, Tyler , Kornak, J M, Kremers, W., Kwan, Justin , Lapid, Maria, Lee, Suzee, Litvan, Irene, Lucente, Diane, Mackenzie, Ian R., Masdeu, J C, Massimo, Lauren, McGinnis, Scott, McMillan, Corey T., Mendez, Mario F., Mester, Carly, Miyagawa, Toji , Molden, Joie, Onyike, Chiadi, Pantelyat, Alexander, Pascual, Belen, Paulson, Henry, Ramanan, Vijay, Rankin, Katherine P., Rascovsky, Katya, Rhoads, Kristoffer , Savica, Rodolfo, Snyder, Allison, Sullivan, A. Campbell, Syrjanen, Jeremy, Tartaglia, M, Taylor, Jack, Tipton, P E, WEINTRAUB, S, Wint, Dylan, Wong, Bonnie, Yokoyama, Jennifer, Paulson, Henry L. , Barmada, Sami J. , Paulson, Henry L , Barmada, Sami , Cobigo, Yann , Worringer, Kathleen A. , Heuer, Hilary W. , VandeVrede, Lawren , Staffaroni, Adam M. , Wolf, Amy , Wise, Amy B. , Sanderson‐Cimino, Mark , Barragan, Eden V. , Grinberg, Lea T. , Seeley, William W. , Casaletto, Kaitlin B. , Kramer, Joel, Ramos, Eliana Marisa , Geschwind, Daniel H. , Forsberg, Leah K. , Gendron, Tania F. , Boeve, Bradley F. , Perneel, Jolien , Rademakers, Rosa , Rosen, Howard J. , Saloner, Rowan , Boxer, Adam L. , Rojas, Julio C. , Appleby, Brian S. , Barmada, Sami, Bayram, Ece , Botha, Hugo, Bozoki, Andrea C , Brushaber, Danielle , Clark, David, Considine, Ciaran , Dickerson, Bradford Clark , Dickson, Dennis, Domoto‐Reilly, Kimiko , Dwosh, Emily , Foroud, Tatiana, Graff‐Radford, Jonathan , Graff-Radford, Neill, Hales, Chadwick M., Honig, Lawrence S. , Hsiung, Ging-Yuek R., Huey, Edward D. , Jones, David T., Kantarci, Kejal , Kornak, John , Kremers, Walter, Kwan, Justin, Léger, Gabriel C. , Litvan, Irene , Lucente, Diane , Mackenzie, Ian R. , Massimo, Lauren , McGinnis, Scott, McMillan, Corey T. , Mendez, Mario F. , Mester, Carly , Pascual, Belén , Ramanan, Vijay, Rankin, Katherine P. , Roberson, Erik D. , Savica, Rodolfo , Snyder, Allison , Sullivan, A. Campbell , Syrjanen, Jeremy A. , Taylor, Jack C. , Tipton, Philip W., Vandebergh, Marijne , Weıntraub, Sandra , Wint, Dylan

Mayo Clinic

JAMA Neurology | June 22, 2026 | Volume: 83 | Issue: 8 | Pages: 778

10.1001/jamaneurol.2026.1927 | PMID 42329632 Get It

Importance TMEM106B is a frontotemporal lobar degeneration (FTLD) genetic susceptibility factor, and TMEM106B protein aggregates are a feature of aging and neurodegeneration. Whether TMEM106B protein levels are associated with clinical features is unknown. Objective To investigate the clinical associations of cerebrospinal fluid (CSF) TMEM106B in FTLD. Design, Setting, and Participants This cross-sectional study was conducted in 2 independent frontotemporal dementia (FTD) cohorts (recruitment from April 2009 through July 2023, with analyses from January 2025 through April 2026), with a 2-year follow up. This multicenter clinical study integrated clinical, genetic, biomarker, and neuroimaging data. Individuals were recruited through the University of California, San Francisco (n = 3733), or ALLFTD (n = 2343). Participants with available CSF were included. A discovery cohort (n = 271) included participants with sporadic neuropathology-confirmed FTLD; presymptomatic or symptomatic carriers of pathogenic variants in C9orf72 , GRN , or MAPT ; or controls. An independent validation cohort (n = 383) included participants with clinically diagnosed sporadic FTD, Alzheimer disease (AD), and controls. Exposures CSF samples for TMEM106B quantification with aptamer proteomics (SomaScan version 3.0 [discovery cohort] and SomaScan version 4.1 [validation cohort]). Main Outcomes and Measures Parametric tests compared the primary outcome, CSF TMEM106B, by disease severity, TMEM106B rs1990622 genotype, sex, clinical syndrome, pathological diagnosis, and pathogenic variant and determined associations with brain volume. Results In the discovery (n = 271; 136 women [51%]; median [IQR] age, 59 [38-80] years) and validation (n = 383; 183 women [48%]; median [IQR] age, 64 [50-78] years) cohorts, lower CSF TMEM106B was associated with more severe disease (β, −0.15; 95% CI, −0.24 to −0.04; P = .003), lower frontotemporal brain volumes (β, 0.42; 95% CI, 0.24-0.61; P &amp;lt; .001), and faster clinical progression (β, −2.21; 95% CI, −3.70 to −0.72; P = .001). Associations of TMEM106B with clinical disease severity were independent of those with neurofilament light chain. TMEM106B levels were influenced by TMEM106B rs1990622 genotype, where individuals with the protective G/G genotype had lower levels than the risk A/A genotype. CSF TMEM106B levels did not differentiate between FTLD subtypes or between FTLD and AD. Conclusions and Relevance Per the results of this cross-sectional study, TMEM106B is detectable in CSF and levels reflect disease severity in sporadic and genetic FTLD and AD, but levels are also influenced by the TMEM106B rs1990622 genotype. CSF TMEM106B could support further studies to understand the mechanisms of disease and develop clinical tools in FTLD and other neurodegenerative diseases.
Remote, self‐administered, smartphone cognitive testing in a registry‐based cohort: Feasibility, reliability, and validity findings
Dhanam, Sreya , Taylor, Jack C. , Fregly, Ray, Kwang, Winnie, Wise, Amy B. , Heuer, Hilary W. , Forsberg, Leah K. , Kramer, Joel H. , Rosen, Howard J., Mackin, R. Scott , Weiner, Michael W., Nosheny, Rachel L. , Boxer, Adam L., Staffaroni, Adam M. , Registry, and the Brain Health, Staffaroni, Adam M , Sanderson‐Cimino, Mark , Paolillo, Emily W. , Maruff, Paul , Boeve, Bradley F. , Boxer, Adam L. , Registry, and the Brain Health

Mayo Clinic

Alzheimer's & Dementia | June 11, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71580 | PMID 42273832 Get It

Abstract BACKGROUND Remote, smartphone‐based cognitive testing may improve access to cognitive assessments for Alzheimer's disease and related dementias. We evaluated the feasibility, reliability, and validity of unsupervised smartphone‐based cognitive tests in a registry‐based cohort. METHODS Adults without a record of cognitive impairment ( N = 1815; ages 18–92) were recruited from the University of California, San Francisco (UCSF) Brain Health Registry to complete three unsupervised smartphone cognitive testing sessions within 2 weeks. Reliability was assessed with correlations between sessions. Linear regression models tested associations of smartphone tasks with demographics, self‐ and informant‐rated cognitive concerns, and web‐based cognitive testing (Cogstate Brief Battery). RESULTS Adherence was high (82.2%) and usability favorable. Test–retest reliability was moderate to strong ( ρ ’s = 0.61–0.85, all p ’s < 0.001). Lower smartphone scores were associated with older age, lower education, cognitive concerns, and worse Cogstate performance. DISCUSSION Findings support the feasibility, reliability, and validity of remote digital assessments in adults without a record of cognitive impairment.
Individualized Atrophy‐Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed‐Effects Modeling
Dutt, Shubir , Leichter, Dana, Wolf, Amy , Kornak, John , Clark, Annie L , Russell, Lucy L. , Bouzigues, Arabella , Cash, David M, Bocchetta, Martina , Olzinski, Molly, Ece, Bayram, Borroni, Barbara, Butler, Chris R., Clark, David, Convery, Rhian S., Darby, R. Ryan , Mendonça, Alexandre de, Dickerson, Bradford, Domoto‐Reilly, Kimiko, Ducharme, Simon, Ferry‐Bolder, Eve, Finger, Elizabeth, Foster, Phoebe H. , Galasko, Douglas R., Galimberti, Daniela, Gerhard, Alexander, Ghoshal, Nupur , Graff, Caroline, Graff‐Radford, Neill, Grant, Ian M., Hales, Chadwick M., Honig, Lawrence S., Hsiung, Ging‐Yuek, Huey, Edward D, Irwin, David John, Jiskoot, Lize C., Kremers, Walter K. , Kwan, Justin Y., Laforce, Robert, Ber, Isabelle Le, Levin, J, Litvan, Irene, Mackenzie, Ian R., Masellis, Mario, Mendez, Mario F., Moreno, Fermin, Onyike, Chiadi U. , Otto, M, Pascual, Belen, Pressman, Peter , Rademakers, Rosa, Ramos, Eliana Marisa , Ritter, Aaron, Roberson, Erik D. , Sánchez‐Valle, Raquel, Santana, Isabel, Seelaar, Harro, Snyder, Allison, Sorbi, Sandro, Synofzik, Matthis, Tartaglia, Maria Carmela, Swieten, John C. van, Vandebergh, Marijne , Vandenberghe, Rik, Heuer, Hilary W. , Miller, Bruce L., Seeley, William W., Gorno‐Tempini, Maria Luisa, Kramer, Joel H., Forsberg, Leah K., Kantarci, Kejal, Boeve, Bradley F., Boxer, Adam L. , Rohrer, J. D., Rosen, Howard J., Staffaroni, Adam M., investigators, FTD Prevention Initiative (FPI), Graff, Caroline , Galimberti, Daniela , Otto, Markus , Jiskoot, Lize C. , Moreno, Fermín , Domoto‐Reilly, Kimiko , Russell, Lucy L , Bocchetta, Martina , Bayram, Ece , Ducharme, Simon , Finger, Elizabeth C. , Galimberti, Daniela , Ghoshal, Nupur , Irwin, David J , Kwan, Justin Y , Le Ber, Isabelle , Otto, Markus , Pascual, Belen , Snyder, Allison , Synofzik, Matthis , Tartaglia, Maria Carmela , Tiraboschi, Pietro , Kantarci, Kejal , Rohrer, Jonathan D , Roberson, Erik , Kremers, Walter K , Domoto-Reilly, Kimiko , Vandebergh, Marijne , Bouzigues, Arabella , Jiskoot, Lize C , Graff, Caroline , Cobigo, Yann , Cash, David M. , Appleby, Brian S. , Borroni, Barbara , Bozoki, Andrea C , Clark, David, Convery, Rhian , Mendonça, Alexandre de , Ducharme, Simon , Ferry‐Bolder, Eve , Galasko, Douglas , Gerhard, Alexander , Graff‐Radford, Neill R. , Hales, Chadwick M. , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kwan, Justin , Laforce, Robert , Ber, Isabelle Le , Léger, Gabriel C. , Xiong, Chengjie , Litvan, Irene , Mackenzie, Ian R. , Masellis, Mario , Mendez, Mario F. , Pascual, Belén , Rademakers, Rosa , Rowe, James B. , Sánchez‐Valle, Raquel , Santana, Isabel , Seelaar, Harro , Snyder, Allison , Sorbi, Sandro , Synofzik, Matthis , Tiraboschi, Pietro , Swieten, John C. van , Vandenberghe, Rik , Seeley, William W. , Gorno‐Tempini, Maria‐Luisa, Kramer, Joel H. , Forsberg, Leah K. , Kantarci, Kejal , Boeve, Bradley F. , Rohrer, Jonathan D. , Rosen, Howard J. , Staffaroni, Adam M.

Mayo Clinic

Annals of Neurology | January 29, 2026 | Volume: 99 | Issue: 5 | Pages: 1315-1326

10.1002/ana.78167 | PMID 41608854 Get It

Objective Age of symptom onset is highly variable in familial frontotemporal lobar degeneration (f‐FTLD). Accurate prediction of onset would inform clinical management and trial enrollment. Prior studies indicate that individualized maps of brain atrophy can predict conversion to dementia in f‐FTLD. We used a Bayesian linear mixed‐effect (BLME) prediction method for identifying accelerated brain volume loss to predict conversion to dementia. Methods Participants included 234 asymptomatic or prodromal carriers of C9orf72 , GRN , or MAPT mutations (including 21 dementia converters) with ≥3 longitudinal magnetic resonance imaging (MRI) T1‐weighted scans. The BLME models established individual voxel‐wise gray matter trajectories using the first 2 scans. Person‐specific clusters of accelerated volume loss were estimated in subsequent scans and tested as predictors of dementia conversion compared with other approaches in time‐varying Cox proportional hazard models covarying for age. Receiver‐operating characteristic (ROC) curves estimated utility of cluster volume in discriminating which participants converted to dementia within 24 months. Results The BLME cluster volume predicted conversion to dementia in f‐FTLD mutation carriers overall and separately in C9orf72 , GRN , and MAPT , with comparable hazard ratios observed for atrophy W‐maps and regional volumes. Within a 24‐month timeframe, BLME cluster volume discriminated dementia converters from non‐converters with larger areas under the curve (AUCs) than other approaches. Interpretation Bayesian‐modeled individualized atrophy scores predict dementia progression among asymptomatic f‐FTLD mutation carriers and may have increased utility compared with other structural imaging methods when studying individuals over shorter timeframes that align with clinical trial design. ANN NEUROL 20269999:n/a–n/a
Distinct Tau PET Dynamics in Early vs. Late Age-of-Onset Alzheimer’s disease
Chiotis, Konstantinos, Soleimani-Meigooni, David N, Aisen, Paul S, Amuiri, Alinda, Atri, Alireza, Beckett, Laurel, Brickhouse, Michael , Clark, David G, Dage, Jeffrey L, Day, Gregory S, Duara, Ranjan, Eloyan, Ani , Foroud, Tatiana, Graff-Radford, Neill R, Grant, Ian M, Hammers, Dustin B, Honig, Lawrence S, Johnson, Erik C. B., Jones, D. Richard, Kirby, Kala, Koeppe, Robert, Kramer, Joel H, Kukull, Walter A, Leuzy, Antoine , Masdeu, Joseph C., Mendez, Mario F., Musiek, Erik, Nudelman, Kelly N., Onyike, Chiadi U., Riddle, Meghan, Rocha, Salma, Rogalski, Emily, Salloway, Stephen, Schonhaut, Daniel R., Sha, Sharon, Shankar, Ranjani, Taurone, Alexander, Thangarajah, Maryanne, Toga, Arthur W., Touroutoglou, Alexandra, Turner, Raymond Scott, Vemuri, Prashanthi, Wingo, Thomas S., Wolk, David A., Womack, Kyle, Zhang, J. , Carrillo, Maria C., Dickerson, Bradford C., Apostolova, Liana G., Joie, Renaud La, Rabinovici, Gil D., Chiotis, Konstantinos , Blazhenets, Ganna , Soleimani‐Meigooni, David N. , Aisen, Paul , Atri, Alireza , Beckett, Laurel , Clark, David G., Dage, Jeffrey L. , Day, Gregory S. , Duara, Ranjan , Foroud, Tatiana , Graff‐Radford, Neill R. , Hammers, Dustin B , Honig, Lawrence S. , Johnson, Erik C. B. , Jones, David T. , Koeppe, Robert A. , Kramer, Joel H. , Kukull, Walter A. , Lagarde, Julien , Maiti, Piyush , Masdeu, Joseph C , Mendez, Mario F. , Musiek, Erik , Nudelman, Kelly , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen, Schonhaut, Daniel R. , Sha, Sharon J. , Shankar, Ranjani , Taurone, Alexander, Thangarajah, Maryanne, Toga, Arthur W. , Touroutoglou, Alexandra , Turner, Raymond Scott , Vemuri, Prashanthi , Wingo, Thomas S , Wolk, David A. , Womack, Kyle , Carrillo, María C. , Dickerson, Bradford Clark , Apostolova, Liana G. , Joie, Renaud La , Rabinovici, Gil D.

Mayo Clinic

No container title available | January 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.25.26344738 | PMID 41646765 Get It

Abstract Early-onset Alzheimer’s disease (EOAD) and Late-onset AD (LOAD) differ in clinical presentations and rates of progression. We aimed to compare baseline and longitudinal tau PET burden, and their relationship with clinical variables in amyloid-PET positive, cognitively impaired participants from the Longitudinal Early-Onset Alzheimer’s Disease Study (EOAD; n=390) and Alzheimer’s Disease Neuroimaging Initiative (LOAD; n=211). Patients with EOAD showed higher baseline tau PET retention, broader neuroanatomical involvement and faster accumulation rates over time compared to LOAD, after adjusting for amyloid load and clinical stage. Tau PET showed stronger correlations with baseline amyloid burden and clinical measures of global cognition and function in EOAD than LOAD. We conclude that earlier age of onset in AD is linked to a more aggressive tauopathy, which in turn is a primary driver of clinical decline. These findings suggest that optimal therapeutic targets and strategies may differ between EOAD and LOAD. One Sentence Summary Younger patients with Alzheimer’s disease show more aggressive tau spread, suggesting age of onset defines distinct disease pathways with key clinical implications.
Alzheimer's disease polygenic risk in early‐ and late‐onset Alzheimer's disease
Pentchev, Julian V., Jackson, Trever, Khan, Naazneen , Rosewood, Thea , Huang, Yen‐Ning, Nho, Kwangslk, Saykin, Andrew J., Eloyan, Ani, Taurone, Alexander, Thangarajah, Maryanne, Riddle, Meghan, Salloway, Steven, Atri, Alireza, Honig, Lawrence S., Johnson, Erik C. B., Turner, Raymond Scott, Masdeu, Joseph C. , Foroud, Tatiana M., Clark, David, Hammers, Dustin B., Dage, Jeffrey L., Kirby, Kala, Ghetti, Bernardino, Newell, Kathy, Onyike, Chiadi U., Day, Gregory S., Graff‐Radford, Neill R., Murray, Melissa E., Jones, D. Richard, Jack, Clifford R., Vemuri, Prashanthi, Touroutoglou, Alexandra, Duara, Ranjan, Grant, Ian, Sha, Sharon, Wingo, Thomas S., Beckett, Laurel A., Rogalski, Emily J, Mendez, Mario F., Kramer, Joel, Joie, Renaud La, Grinberg, Lea T., Koeppe, Robert, Wolk, David A., Aisen, Paul, RAMAN, REMA , Toga, Arthur, Kukull, Walter A., Musiek, Erik, Womack, Kyle, Carrillo, Maria C., Rabinovici, Gil D., Dickerson, Bradford C., Apostolova, Liana G., Nudelman, Kelly N. H., Murray, Melissa E. , Carrillo, María C. , Turner, Raymond Scott , Rabinovici, Gil D. , Joie, Renaud La , Day, Gregory S. , Day, Gregory S , Murray, Melissa E , La Joie, Renaud , Rabinovici, Gil D , Huang, Yen‐Ning, Nho, Kwangsik T. , Saykin, Andrew J. , Eloyan, Ani , Taurone, Alexander, Riddle, Meghan , Salloway, Steve , Atri, Alireza , Honig, Lawrence S. , Johnson, Erik C. B. , Masdeu, Joseph C , Foroud, Tatiana , Clark, David, Hammers, Dustin B , Dage, Jeffrey L. , Ghetti, Bernardino , Newell, Kathy L. , Onyike, Chiadi U. , Graff‐Radford, Neill R. , Jones, David T. , Jack, Clifford R. , Vemuri, Prashanthi , Touroutoglou, Alexandra , Duara, Ranjan , Sha, Sharon J. , Beckett, Laurel , Rogalskı, Emily , Mendez, Mario F. , Kramer, Joel, Blazhenets, Ganna , Grinberg, Lea T. , Koeppe, Robert A. , Wolk, David A. , Aisen, Paul , Toga, Arthur W. , Kukull, Walter A. , Musiek, Erik , Dickerson, Bradford Clark , Apostolova, Liana G. , Nudelman, Kelly

Mayo Clinic

Alzheimer's & Dementia | January 14, 2026 | Volume: 22 | Issue: 1 | Pages: No page available

10.1002/alz.71066 | PMID 41532810 Get It

Abstract INTRODUCTION The genetic basis of sporadic early‐onset Alzheimer's disease (EOAD) remains largely unknown, prompting evaluation of late‐onset Alzheimer's disease (LOAD) polygenic risk in EOAD. METHODS A LOAD polygenic score (PGS) was calculated in the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) and Alzheimer's Disease Neuroimaging Initiative (ADNI) study and tested for associations with AD risk, cognitive performance, and imaging and fluid biomarkers. RESULTS Though PGS was elevated in LOAD and EOAD, it was not a significant predictor of EOAD adjusting for APOE ε4 carrier status and was not associated with age of EOAD onset ( p = 0.106) or with cognitive performance ( p = 0.417). In LEADS, greater LOAD PGS was associated with differences in neuroimaging and fluid biomarkers, including elevated synaptosomal‐associated protein 25 (SNAP‐25) ( p = 2.3 × 10 −5 ). DISCUSSION While LOAD polygenic risk contributed minimally to EOAD onset and cognitive dysfunction, PGS association with fluid biomarkers in LEADS suggests a role for LOAD polygenic risk in EOAD pathophysiology. Highlights LOAD PGSs were elevated in both LOAD and EOAD compared to controls; however, LOAD PGS did not significantly predict EOAD risk, age at onset, or cognitive performance independent of APOE ε4 in the LEADS. Higher LOAD PGS was associated with lower amyloid PET Centiloids (less brain amyloid deposition) as well as lower CSF biomarker Aβ42 in LEADS (proxy marker suggesting higher brain amyloid deposition) in LEADS; these contradictory findings support the need for larger studies to further investigate whether LOAD PGS is associated with increased amyloid deposition in EOAD. Higher LOAD PGS was also associated with higher levels of CSF synaptosomal‐associated protein 25 (SNAP‐25), a key component of the SNARE complex, suggesting that LOAD genetic factors may contribute to dysregulation of synaptic transmission and/or pathological protein aggregation in EOAD.
Every Centiloid, from Everywhere, All at Once
Snyder, Heather M. , Apostolova, Liana G., Asken, Breton M., Bombois, Stéphanie, Bourgeat, Pierrick, Braskie, Meredith N., Carrillo, Maria C., Casaletto, Kaitlin B, Cash, David M, Chang, Hsin‐I., Chao, Yishu , Chételat, Gael, Collij, Lyduine E., Dickerson, Brad C., Dubois, Bruno, Valdez, Alfonso Fajardo, Farrar, Gill , Fortea, Juan M., Frisoni, Giovanni B, Gu, Yuna , Guo, Tengfei, Hanseeuw, Bernard J, Hansson, Oskar H., Harrison, Theresa, Huang, Qi, Huang, Shu‐Hua , Ishii, K, Ishii, Kenji, Jagust, William J., Katou, Rikio, Koeppe, Robert A., Kramer, Joel H, Landau, Susan M., Landeau, Brigitte, Lee, Sangwon, Lopresti, Brian J, Lowe, Val J. , Mao, Xiaoxie, March, Andrew, Masters, Colin L., Mézenge, Florence, Mormino, Elizabeth C., Franquesa‐Mullerat, María , Nakamura, Akinori, O'Bryant, Sid E., Pappas, Ioannis, Rowe, Christopher C., Salvadó, Gemma, Schott, Jonathan M, Schwartz, Daniel, Schwarz, Christopher G, Seo, Sang Won, Shekari, Mahnaz , Silbert, Lisa C, Smith, Ruben, Sokolowski, Andrzej, Soleimani‐Meigooni, David, Sperling, Reisa A., Sun, Pan , Toga, Arthur W., Vaillancourt, D., Giessen, Elsmarieke van de, Flier, Wiesje M. van der, Vemuri, Prashanthi, Villemagne, Victor L., Villeneuve, Sylvia , Wang, Wei‐En, Weiner, Michael S. W., Xiao, Cally , Xie, Fang, Yoon, Yeojun, Yun, M R , Rabinovici, Gil D., Joie, Renaud La, Consortia, AMYPAD and LEADS, Blazhenets, Ganna , Apostolova, Liana G. , Asken, Breton M. , Bejanin, Alexandre , Bombois, Stéphanie , Bourgeat, Pierrick , Braskie, Meredith N. , Carrillo, María C. , Casaletto, Kaitlin B. , Cash, David M. , Chang, Chia‐Hsuin , Chang, Hsin‐I , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Bradford Clark , Dubois, Bruno , Fortea, Juan , Frisoni, Giovanni B. , Gardner, Raquel C. , Garibotto, Valentina , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Ishii, Kenji, Jagust, William J. , Koeppe, Robert A. , Kramer, Joel H. , Landau, Susan , Landeau, Brigitte , Lee, Sangwon, Lopresti, Brian J. , March, Andrew, Masters, Colin L. , Mézenge, Florence, Mormino, Elizabeth C. , Nakamura, Akinori , O’Bryant, Sid E. , Pappas, Ioannis , Peretti, Débora Elisa , Quenon, Lisa , Rowe, Christopher C., Salvadó, Gemma , Schott, Jonathan M. , Schwartz, Daniel L., Schwarz, Christopher G. , Seo, Sang Won , Shekari, Mahnaz , Silbert, Lisa C. , Smith, Ruben, Soleimani‐Meigooni, David N. , Sperling, Reisa Anne , Sun, Pan , Toga, Arthur W. , Vaillancourt, David E. , Giessen, Elsmarieke van de , Flier, Wiesje M. van der , Vemuri, Prashanthi , Villain, Nicolas , Villemagne, Victor L. , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Rabinovici, Gil D. , Joie, Renaud La

Mayo Clinic

Alzheimer's & Dementia | January 9, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107124 Get It

Abstract Background Ten years after the original publication, the Centiloid framework is now broadly used to harmonize amyloid‐PET quantification, facilitate data sharing and comparison across cohorts, and even assist visual interpretation in clinical settings. We evaluated the global implementation of Centiloids by comparing their distribution and corresponding positivity thresholds across cohorts. Methods We gathered data from publicly available cohorts and reached out to investigators across the world to collect cross‐sectional Centiloids, demographic and clinical information, and visual read data. Gaussian mixture models (GMM, k=2) were fitted to Centiloid values for each cohort and cutoffs were calculated as mean + 2SD of the lower Gaussian. When visual reads were available, we determined Centiloid cutoffs that maximized correspondence with visual reads (Cohen's kappa). Data was combined across cohorts using random effects meta‐analyses. Results As of January 2025, we included 37 cohorts ( n = 41,678 participants) with heterogeneous pipelines, radiotracers, and clinical and demographic characteristics (Table‐1). The low Gaussian peaks ranged from ‐9 to 10CL; the meta‐analysis identified a common peak at 1CL. The second peaks were more heterogeneous (range=38‐102CL; meta‐analysis outcome=64CL). Across cohorts, the proportion of cognitively unimpaired versus impaired participants impacted the position of both peaks, with better separation in cohorts enriched in impaired individuals (Figure 1C). The meta‐analysis indicated a GMM‐based cutoff of 19CL (95%CI: 16‐21CL, Figure 1B); subgroup analyses showed no evidence of significant effect between single versus multicenter settings (17 versus 20CL, p = 0.30), MRI‐based or PET‐only processing (18 versus 19CL, p = 0.88), and no evidence of difference across radiotracers (Flutemetamol: 16CL; PIB: 17CL, Flutafuranol: 18CL, Florbetaben: 19CL, Florbetapir: 20CL, p = 0.78). In a subset of 29,496 participants with visual reads available, binary visual reads corresponded well to Centiloids (common kappa=0.86, Figure 2A). The visual read‐based cutoff of 24CL (95%CI: 21‐27CL, Figure 2B) maximized correspondence between visual read and quantification and was slightly higher than the GMM‐based cutoff. All meta‐analysis models showed high non‐random heterogeneity (I 2 >80%) across studies, suggesting non‐random differences in peaks and cutoffs. Conclusions Meta‐analysis‐based cutoffs align well with thresholds from the existing literature. High heterogeneity among studies underscores the need to investigate contributing factors, raising concerns about applying common cutoffs.